Given the urgent need to advance cervical cancer care, especially in developing economies, Elekta has made a significant contribution to support the IAEA initiative. This contribution is being made in the form of brachytherapy training modules that Elekta has developed with its clinical partners through the Elekta BrachyAcademy, a peer-to-peer educational platform. This module will be used to train physicians and medical physicists within the countries supported by the partnership. As part of this training module, Elekta is also providing demonstration equipment, workstations, materials for the training, and support of clinical application specialists.
A recent study found that, while cervical cancer is the fourth most common cancer in women globally, it is the leading cause of cancer-related death in women in eastern, western, middle and southern Africa.
1st FDA Approved Handheld Wireless Ultrasound Probe.Currently being used to fight COVID-19 in Wuhan China, South Korea, & within the USA.Features include Lung Ultrasound Scanning, & PACS Compatibility. ( CONTACT US TODAY TO RESERVE INVENTORY )
Brachytherapy enables personalized, precision radiation medicine in the treatment of cervical cancer and with 3D images, it allows more precise targeting of the radiation, which can allow a higher dose to be used while still protecting healthy tissue. This may increase efficacy while also reducing patients’ treatment burden by allowing the full dose to be delivered over fewer treatment sessions.
Ensuring that women with cervical cancer receive treatment that includes brachytherapy is essential for improving health outcomes.
My hope is that Elekta’s contribution to this initiative will help to spread the use of brachytherapy in the treatment of cervical cancer to other hospitals and countries. Our vision is that the participants in the program will go on to establish centers of brachytherapy excellence within their home institutions, and that these centers will allow them to share knowledge and best practices with other radiation oncologists and medical physicists within their countries and global regions.
Increasing global access to all radiotherapy solutions is a key Elekta mission for 2020 and the decade ahead. We are grateful that so many others around the world share this vision and are implementing collaborative programs that recognize the important role that industry has to play in addressing the global cancer epidemic and provide us with opportunities to contribute. Addressing cancer across genders, countries, societies and economies requires that all of us do our part.
On World Cancer Day, I encourage each of you to find ways to make a difference in the life of patients living with cancer. I am Richard Hausmann, and I will continue to ensure that Elekta provides real-world solutions to the challenges that patients with cancers and those who care from them face every day.
Back to HCB News